Nuvectra Corporation

Nuvectra — B. Riley Investor Conference (May 2017)

20 slides from Nuvectra's conference presentation, May 24, 2017

  1. Slide 1: New Directions in Neurostimulation

    Slide 1: New Directions in Neurostimulation

    NUVECTRA B. Riley Investor Conference New Directions in Neurostimulation May 24, 2017

  2. Slide 2: Legal Disclaimer

    Slide 2: Legal Disclaimer

    Legal Disclaimer Forward Looking Statements This presentation contains "forward-looking statements,” including statements we make regarding the outlook for Nuvectra as an independent publicly-traded company. Forward-looking statements are based only on our current beliefs, expectations and assumptio

  3. Slide 3: Nuvectra Spin Off

    Slide 3: Nuvectra Spin Off

    Nuvectra Spin Off Greatbatch ‘The Spin’ 2009-2015 March 14% 2016 $75M Funding Greatbatch Funded R&D $45M2) Phase Design & Development Commercialization MARKET RESEARCH REGULATORY COMPANY Biber CLINICAL SALES & CONCEPT | VERIFICATION FORMATION & VALIDATION MARKETING STRATEGY QUALITY QiG NUVECTRA (1)

  4. Slide 4: Nuvectra Positioned for Success

    Slide 4: Nuvectra Positioned for Success

    Nuvectra Positioned for Success Nel ff 7] Large & Growing Platform Algovita SCS Focused on Target Markets Technology System Growth ~$2.8B *Spinal Cord + Expansive +Powerful IPG *Build world class Stimulation (SCS) IP portfolio *Stretchable leads distribution team * Sacral Nerve +Access to multiple «

  5. Slide 5: Neurostimulation Targeted Market Opportunity

    Slide 5: Neurostimulation Targeted Market Opportunity

    Neurostimulation Targeted Market Opportunity ~$2.8B Target Market ~7.5% CAGR through 2018 SNS Market) DBS Market) ail 42% 4 96% Chronic Pain Bladder & Bowel Control Movement Disorders ~$1.7B ~$570M ~$600M ~6% CAGR ~9.5% CAGR ~10% CAGR oan $750 $725 sig $19 $20 $690 $650 $1.7 $630 $600 $1.6 $520 $570

  6. Slide 6: Platform Designed for Multiple Indications

    Slide 6: Platform Designed for Multiple Indications

    Platform Designed for Multiple Indications Expansive Proprietary IP Portfolio 164 Issued 104 Pending Physician & Patient Programmers Proprietary Processors NUVECTRA

  7. Slide 7: SCS — Our First Opportunity

    Slide 7: SCS — Our First Opportunity

    SCS — Our First Opportunity Chronic Pain\".2) + 1.5B WW suffer from chronic pain Chronic pain is a + 100M Americans suffer from severe and chronic pain significant medical, economic and social problem + $300B annual healthcare spend in the US * Chronic pain sufferers are also affected with depressio

  8. Slide 8: World Renowned SCS Physician Advisors

    Slide 8: World Renowned SCS Physician Advisors

    World Renowned SCS Physician Advisors Giancarlo Barolat, MD | Chief Medical Advisor + Professor of Neurosurgery, Thomas Jefferson University, Philadelphia, PA (1985-2005) + Director, Barolat Neuroscience Center at Presbyterian St. Luke’s Hospital, Denver, CO (2005-present) + Director of Barolat Neur

  9. Slide 9: Experienced Leadership Team

    Slide 9: Experienced Leadership Team

    Experienced Leadership Team Scott Drees | CEO & Director bs + QIG Group , CEO & Founding Partner if + Founding Division President, Advanced Neuromodulation Systems Inc. (ANSI) + Prior experience: St. Jude Medical, Boston Scientific, Johnson & Johnson + 35yrs. implantable medical devices experience;

  10. Slide 10: Algovita SCS System

    Slide 10: Algovita SCS System

    Algovita SCS System Powerful Versatile Usable NUVECTRA

  11. Slide 11: Powerful IPG Therapy Delivery

    Slide 11: Powerful IPG Therapy Delivery

    Powerful IPG Therapy Delivery + 24 channels + 24 current sources + Large battery capacity + Broad parametric ranges * Bi-directional recharge + Embedded program memory Proprietary Stimulation & Power Processors *: ) Configuration 2x8 2x8 a8 2x8 # of Channels 24 16 16 32 16 # of Power Sources 24 1 1

  12. Slide 12: A New Generation of Lead Design

    Slide 12: A New Generation of Lead Design

    A New Generation of Lead Design 7 Algovita . Market Opportunities + Increase spinal coverage + Lead stretchability + Reduce lead kinkage, breakage, and migration (13%) () COIL DESIGN UNCONSTRAINED INDEPENDENT COIL IN COIL DESIGN COIL STRUCTURE STRAIGHT WIRE STRAIGHT WIRE DUAL COIL STRUCTURE 4-Electr

  13. Slide 13: Simplifying Programming Complexity

    Slide 13: Simplifying Programming Complexity

    Simplifying Programming Complexity Patient Clinician + Wireless telemetry + Colored touchscreens * Highly intuitive + Patient interactive programming + Discreet & portable patient control Competitive Devices") Patient Controllers PatientIPG Rechargers NUVECTRA

  14. Slide 14: Algorithm for SCS Success

    Slide 14: Algorithm for SCS Success

    Algorithm for SCS Success 1. Intra-operative: Traditional Placement A. Place leads B. Confirm lead position C. Close 2. Post-operative: Patient Interactive Programming & Optimization Mm ta A. Patient identifies B. Optimize stimulation C. Provide activity optimal contacts program options 3. Daily Usa

  15. Slide 15: U.S. Commercialization

    Slide 15: U.S. Commercialization

    U.S. Commercialization Hire Proven Team of Sales Talent * Build world class team H + Foster high achieving culture Sales management, national account coverage, direct reps, * Focus on SCS market share sales agents, clinical specialists + Initiate clinical studies - U.S. Algovita sales team of ~70 +

  16. Slide 16: Virtis SNS System — Our Second Opportunity

    Slide 16: Virtis SNS System — Our Second Opportunity

    Virtis™ SNS System — Our Second Opportunity Indications Urinary Incontinence + Designed forthe treatment of chronic urinary retention and the symptoms of overactive bladder Regulatory Submissions Have Been Filed with the FDA and CE Mark Authorities Pulse ‘Generator Bladder Market Opportunity 20+ yrs

  17. Slide 17: Strategic Development Agreement

    Slide 17: Strategic Development Agreement

    Strategic Development Agreement alev + Development agreement through 2017 + Nuvectra to license platform of IPG and programmers to Aleva for royalties + Aleva provides MEMS technology with directSTIM directional DBS lead + Field of use: DBS for Parkinson's Disease (PD) NUVECTRA DBS Market Opportunit

  18. Slide 18: NeuroNexus

    Slide 18: NeuroNexus

    4} NeuroNexus Designs, develops and manufactures leading edge neuroscience technology and devices for clinical research markets Neurostim Penetrating Deep Brain Surface Groce | Drug Chemical Nerve Delivery Sensing MRI Optogenetics Smartbox™ High-performance 256 channel recording system Provides earl

  19. Slide 19: Nuvectra Positioned for Success

    Slide 19: Nuvectra Positioned for Success

    Nuvectra Positioned for Success Nel ff 7] Large & Growing Platform Algovita SCS Focused on Target Markets Technology System Growth ~$2.8B *Spinal Cord + Expansive +Powerful IPG *Build world class Stimulation (SCS) IP portfolio *Stretchable leads distribution team * Sacral Nerve +Access to multiple «

  20. Slide 20: THANK YOU!

    Slide 20: THANK YOU!

    THANK YOU! F RUQgSatee? SU Lali iVAGN Nuvectra’s Spinal Cord Stimulator ; en Receives Frost & Sullivan's AWARD 2017 New Product Innovation Award NUVECTRA

Source: SEC EDGAR · 8-K filed May 24, 2017

More decks from Nuvectra Corporation